Puma Biotechnology Number Of Shares Shorted vs. EBITDA
| PBYI Stock | USD 6.15 0.15 2.50% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.86 | 0.7453 |
|
|
The profitability profile for Puma Biotechnology reflects how income compares to revenue, assets, and capital. All values are derived from reported financial statements.
Puma Biotechnology's Segment Revenue Breakdown
Puma Biotechnology's revenue is distributed across 2 distinct product categories. Puma Biotechnology's revenue is anchored by Product (59.88 Million, 79.4%), followed by Royalty (15.57 Million, 20.6%). A single segment driving over 60% of revenue suggests limited product diversification, which can amplify both upside and downside.
Your Equity Center.
Macro event markers
Revenue Breakdown by Earning Segment for Puma Biotechnology Details
Puma Biotechnology's product-level revenue split is shown below, highlighting each segment's share of total revenue. At 20.6%, Royalty is the narrowest segment in Puma Biotechnology's product mix.
Forward-looking earnings context helps frame Puma Biotechnology performance expectations. The estimates are presented as context for broader analysis and timeframe comparison. The dataset draws on income statement, balance sheet, and cash flow disclosures. The information is analytical in nature and is not intended as a specific recommendation.
Quarterly Earnings Growth -0.34 | Earnings Share 0.61 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than book value, which reflects Puma accounting equity. Puma Biotechnology's market capitalization is 312.89 M. A P/B ratio of 2.34 indicates the market values Puma Biotechnology above its accounting book value. Enterprise value stands at 236.28 M. Intrinsic value reflects what Puma Biotechnology's fundamentals imply about worth, which may differ from both price and book figure. Valuation work aligns these measures into a single analytical context. This dataset reflects observed data and is not advisory in nature.
The concept of value for Puma Biotechnology differs from its quoted price, since each reflects a different lens. For Puma Biotechnology, key inputs include a P/E ratio of 18.52, a P/B ratio of 2.34, a profit margin of 13.62%, and ROE of 27.97%. By contrast, Puma Biotechnology market price reflects the level where buyers and sellers transact. This summary reflects available observations without forecasting intent.
Puma Biotechnology EBITDA vs. Number Of Shares Shorted Fundamental Analysis
Sector-based pricing multiples position Puma Biotechnology within its competitive valuation range. Puma Biotechnology is rated below average for number of shares shorted among direct rivals. It claims the number one ranking for ebitda among direct rivals recording roughly 14.17 in EBITDA for every unit of Number Of Shares Shorted. Market-adjusted estimates suggest EBITDA is likely to increase significantly. According to the most recent annual data, EBITDA was 53.34 Million. Valuation multiples such as P/E, P/B, and P/S compare Puma Biotechnology to peer earnings performance.Puma EBITDA vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Puma Biotechnology |
| = | 3.76 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company's operating cash flow based on data from the company's income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Puma Biotechnology |
| = | 53.34 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Puma EBITDA Comparison
Puma Biotechnology is currently under evaluation for ebitda among direct rivals.
Puma Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Puma Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Puma Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Puma Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Puma Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | 36 K | 37.8 K | |
| Operating Income | 37.3 M | 39.2 M | |
| Income Before Tax | 35.8 M | 37.6 M | |
| Net Income | 31.1 M | 32.7 M | |
| Net Income From Continuing Ops | 31.1 M | 32.7 M | |
| Non Operating Income Net Other | -10.5 M | -10 M | |
| Total Other Income Expense Net | -1.5 M | -1.6 M | |
| Net Income Applicable To Common Shares | 2.3 K | 2.4 K | |
| Income Tax Expense | 4.7 M | 4.9 M | |
| Net Interest Income | -2.5 M | -2.7 M | |
| Interest Income | 4.1 M | 2.1 M | |
| Change To Netincome | 21.7 M | 20.6 M | |
| Net Income Per Share | 0.62 | 0.65 | |
| Income Quality | 1.34 | 1.41 | |
| Net Income Per E B T | 0.87 | 0.70 |
Puma Profitability Driver Comparison
Profitability drivers are factors that directly affect the investment outlook for Puma Biotechnology. Investors recognize that outcomes may not unfold as predicted, because unforeseen events and market disruptions can arise at any point and significantly alter the earnings trajectory.
Earnings per Share Projection vs Actual
Use Puma Biotechnology in pair-trading
Pair trading with Puma Biotechnology can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Puma Biotechnology Pair Trading
Puma Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to Puma Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Puma Biotechnology when you sell it.
The correlation of Puma Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1.
Pair evaluation and Correlation analysis for Puma Biotechnology provide hedging context. The context can be applied within sectors, industries, or broader universes.Use Investing Themes to Complement your Puma Biotechnology position
With 312.89 Million market cap in the Biotechnology industry, Puma Biotechnology works well as a smaller-cap core holding around which broader thematic baskets can be built. Anchoring a Biotechnology theme around Puma Biotechnology at 312.89 Million can be tuned for upside participation or tighter downside control depending on Healthcare outlook.
Did You Try This Idea?
Run Crypto And Gold Thematic Idea Now
Crypto And Gold
Assets that cancel away each other volatility by providing diversification into gold investment combined with digital assets. The Crypto And Gold theme has 54 constituents at this time.
Investors can hold the Crypto And Gold Theme as a long-term basket or actively trade individual constituents to capture short-term price movement.
| View All Next | Launch |